Forte Biosciences Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Forte Biosciences Inc
Access all reports
Forte Biosciences Inc. is a clinical-stage biopharmaceutical company in the United States. The company focuses on the development of first-in-class oral drugs for cancer, inflammation and fibrosis. Its lead product candidate is a dual inhibitor of chitin synthesis and metalloproteinases (NanoFol14) for the treatment of solid tumors including lung cancer, pancreatic cancer, glioblastoma and other cancers. The company is also developing ubenimex (a CCR5 antagonist), which is used for HIV entry inhibition; and an anti-angiogenesis drug for treating pancreatic cancer and other indications.
Latest articles
Daniel Ek: Co-founder and CEO of Spotify
Explore Daniel Ek's journey from a tech-savvy teenager to the co-founder and CEO of Spotify and the most influential person in the music industry.
28 Mar 2024
Companies That Had Their IPO in 1992: A Cautiously Optimistic Market
1992 marked a relatively cool IPO landscape and stock market sentiment, in the wake of the early 90s recession.
28 Mar 2024
Remembering Daniel Kahneman: Transforming Psychology and Economics
Explore Daniel Kahneman's legacy in psychology and economics, highlighting his impact on decision-making and behavioral economics.
28 Mar 2024
Ticker symbol
Country
🇺🇸 United States